Tom Brady has been named the chief wellness officer of eMed, a telehealth firm focused on making GLP-1 weight-loss drugs more affordable [1].
The appointment signals a strategic push by the Miami-based company to leverage high-profile leadership to scale its population-health platform. By targeting the high cost of GLP-1 therapies, eMed aims to help employers provide these treatments to their workforce more sustainably [2, 3].
Brady, a seven-time Super Bowl champion [1], appeared with eMed CEO and former X CEO Linda Yaccarino at the Milken Global Conference in California to discuss the venture [4]. The duo discussed the surge in demand for weight-loss medications and the necessity of a joint venture to lower the financial barriers associated with these drugs [3].
The company is expanding its operations following a significant capital injection. On March 26, 2026, eMed disclosed a funding round that raised $200 million [2]. This investment has pushed the company's valuation to more than $2 billion [2].
Brady's role as chief wellness officer was first announced on Jan. 12, 2026 [1]. The partnership combines Yaccarino's executive experience, and Brady's public image regarding health and performance, to promote the platform's ability to manage chronic conditions at scale [2, 3].
As the demand for GLP-1 medications continues to rise, eMed is positioning itself as a bridge between pharmaceutical providers and corporate health plans. The platform focuses on population health, which allows employers to cover therapy for employees while managing the overall cost of care [3].
“Tom Brady has been named the chief wellness officer of eMed.”
The entry of Tom Brady and Linda Yaccarino into the telehealth space reflects a broader trend of celebrity-backed health ventures targeting the lucrative GLP-1 market. By focusing on employer-sponsored coverage, eMed is attempting to solve the primary barrier to GLP-1 adoption—cost—while leveraging a multi-billion dollar valuation to compete with traditional healthcare providers.
